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A COMPARATIVE ANALYSIS OF REMISSION RATES AND LENGTH OF 
STAY OF PATIENTS WITH DE-NOVO AML AND PATIENTS WITH AML 
WITH UNDERLYING MDS IN A COMMUNITY HOSPITAL SETTING 
 
ADITHI SRINIVASIAH 
ABSTRACT 	
             Acute Myeloid Leukemia (AML) is a type of cancer that affects the process of 
hematopoiesis. In individuals affected with AML, normal blood cells do not develop into 
red blood cells, white blood cells, and platelets, leading to symptoms such as anemia, 
neutropenia, and thrombocytopenia. The prognosis of AML is affected by multiple factors 
including: the genetic make-up of the leukemic cells, age of the affected individual, and 
underlying blood disorders such as myelodysplastic syndrome (MDS). MDS affects the 
development of stem cells into red blood cells, white blood cells, and platelets. Due to their 
clinical heterogeneity, AML and MDS continue to be a challenge that should be 
investigated in the community hospital setting. Remission rates between patients diagnosed 
with de-novo AML and patients diagnosed with AML with MDS were compared in a 
community hospital setting following induction therapy using a retrospective study design. 
Length of stay between patients diagnosed with de-novo AML and patients diagnosed with 
AML with MDS was compared during induction therapy. The association of age at 
diagnosis and number of chromosomal abnormalities to remission status was evaluated in 
each disease group. The association of blood transfusion requirements and neutropenic 
fever to length of stay was evaluated in each disease group. There were no statistically 
	 vi	
significant differences found between disease groups with respect to remission rates and 
length of stay. There were no statistically significant associations found between blood 
transfusion requirements and neutropenic fever in each disease group. There was an 
association found between age at diagnosis and remission status in patients diagnosed with 
AML with MDS. This indicates that older patients with AML with MDS are less likely to 
benefit from therapy and achieve complete remission. It is important to consider the small 
sample size, rare nature of the disease, and other variables that could have contributed to 
trends seen in the study population. The impact of predictors such as growth factor use and 
incidence of fungal infections should be investigated in future studies with AML patients. 
Considering these factors will allow for the development of targeted therapies and 
mechanisms against drug resistance for affected individuals.  
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INTRODUCTION/BACKGROUND 
 
Acute myeloid leukemia (AML) is a type of cancer of the blood and bone marrow. This 
cancer affects the process of hematopoiesis, or the production of blood cells. In particular, 
this disease affects the development of myeloid cells, a group of progenitor cells, that 
normally develop into red blood cells, white cells, and platelets.1   In individuals with AML, 
myeloblasts, or immature myeloid cells, accumulate in the bone marrow and do not mature 
into normal cells, thus leading to common symptom such as anemia (low red blood cell 
count), increased number of infections due to neutropenia (a low white blood count), and 
easy bruising/bleeding due to thrombocytopenia (a low platelet count).1,2 
 
  
                         
     
AML is usually found in the blood and bone marrow, but can easily spread to other parts 
of the body such as the brain, skin, and gums.1 This leukemia is predominantly found in 
males and in adults ages 60 and older. It occurs at an overall rate of 4.0 cases for every 
100,000 people per year. 1,2,3 Individuals suffering from AML have a 26.6% chance of 
surviving 5 years post-treatment.3 Chemotherapy is the most common treatment regimen 
used to treat AML, and is used to kill off the leukemic cells by stopping their ability to 
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grow and divide. Chemotherapy for AML is divided into three phases: induction therapy, 
post-remission therapy, and consolidation or maintenance therapy. Induction therapy is 
defined as the first period of treatment after diagnosis, and the goal of induction therapy is 
to achieve complete remission. Post-remission therapy is defined as period of treatment 
used to kill off leukemic cells that cannot be easily detected by medical tests and imaging. 
Consolidation or maintenance chemotherapy is defined as intensive treatments used to 
prevent the recurrence of AML. 1,2,4 Cytarabine and idarubicin is a two-tiered 
chemotherapeutic regimen used to treat younger patients suffering from AML by targeting 
DNA synthesis in leukemic cells.5 The type of treatment for this disease varies and depends 
upon prognostic factors including the sub-type of AML, the genetic make-up of the 
leukemic cells, general health, age of the affected individual, and underlying blood 
disorders such as myelodysplastic syndrome (MDS). 1,2 
Myelodysplastic Syndrome (MDS) is a disorder of the bone marrow that damages the 
blood-forming cells, and prevents orderly hematopoiesis, or the production of blood 
cells.6,7 In individuals with MDS, the stem cells in the bone marrow have been damaged, 
and do not develop into mature red blood cells, white blood cells, and platelets. 
Approximately 13,000 people a year in the US are diagnosed with MDS.6,7,8 The standard 
of care for treating MDS include: supportive care, drug therapy, and chemotherapy. Blood 
Transfusions, antibiotics, and growth factors are often given when appropriate to boost the 
immune system of affected individuals.6,7 Current therapies for MDS have achieved 
favorable responses, but only in a small subset of patients.7 MDS can be classified into the 
following categories based on the American-British (FAB) Classification System:  
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o Refractory Anemia with Ringed Sideroblasts (RARS) – 15% 
o Refractory Anemia without Ringed Sideroblasts (RA) – 10% 
o Refractory Anemia with Excess Blasts (RAEB) – 40%  
o Refractory Anemia with Excess Blasts in Transformation  
(RAEB-T) – 60%6 
This classification system is based upon changes in the blood cells and the bone marrow. 
The clonal nature of MDS makes it susceptible to transformation into AML and this applies 
in approximately 30% of cases.9 The rate at which this transformation occurs varies based 
on the subtypes of MDS described above.6,7,8, 15  Refractory anemia (RA) is a subtype of 
MDS in which anemia is the primary symptom, and this subtype does not transform into 
AML very often. Refractory Anemia with Ringed Sideroblasts (RARS) is a subtype of 
MDS characterized by anemia and a large number of sideroblasts, a red blood cell in which 
the iron forms a ring in the center of the cell. People diagnosed with this subtype of MDS 
have a low risk (10%) of developing AML. Refractory Anemia with Excessive Blasts 
(RAEB) is a subtype of MDS in which individuals have a decrease in blood cell counts, 
and has a moderate risk (40%) of transforming into AML. Refractory Anemia with 
Excessive Blasts in Transformation is a subtype of MDS that has a high risk (60%) of 
transforming into AML.10 
The transformation of MDS into AML is a type of secondary AML that has been shown 
to have refers to AML that occurs without a pre-existing condition such as MDS or 
previous cancer treatments. The poorer prognosis of patients diagnosed with AML with 
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underlying MDS has been linked to factors such as older age, anemia, neutropenia, multiple 
cytogenetic abnormalities, and associated multi-drug resistance mechanisms.7  
The clinical heterogeneity of AML with underlying MDS presents many diagnostic and 
therapeutic challenges for physicians and researchers. While previous studies have 
addressed some of the predictors of prognosis of secondary AML, it would be beneficial 
to address the varied response and predictors of prognosis of AML with underlying MDS 
in the community hospital setting, to assess clinical outcomes. Therefore, the primary 
objective of this study was to compare the remission rates of patients diagnosed with de-
novo AML and patients diagnosed with AML with underlying MDS following induction 
therapy at Dekalb Medical Center, a community hospital located in Atlanta, GA.  Since 
initial induction therapy and remission induction has the greatest impact on long-term 
survival benefit, it was chosen to be the main focus of this study. In this study, complete 
remission is defined as “Normal values for absolute neutrophil count (>1000/microL) and 
platelet count (>100,000/microL), and independence from red cell transfusion. A bone 
marrow biopsy that reveals no clusters or collections of blast cells. Extramedullary 
leukemia (eg, central nervous system or soft tissue involvement) must be absent.”11 
Since the prognosis of patients can also be influenced by patient-specific factors and 
disease-specific factors such as age and chromosomal abnormalities, the association of 
these predictors with remission was also evaluated in each disease group.12 This will 
hopefully improve the understanding of the benefit of specific treatment approaches and 
differences in clinical outcomes to improve quality of care for these patients in a 
community hospital setting.  
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Infections are the most common complications affecting the morbidity and mortality of 
patients affected with AML.13,14 These infections not only contribute to mortality, but also 
can prolong hospitalizations and affect the quality of care of patients.14 It has been shown 
that patients diagnosed with AML with underlying MDS have a higher propensity to 
develop infections, anemia, and febrile neutropenia accompanied by multiple cytogenetic 
abnormalities.7,16 Febrile neutropenia caused by therapy can increase the number of 
infections, requiring the patient to be hospitalized and administered antibiotics to minimize 
mortality.17  Previous studies have shown that neutropenic cancer patients who require 
prolonged length of stay may be more susceptible to developing drug resistance, have 
delays in treatment, and may be faced with large financial expenditures.17 Therefore, the 
secondary objective of this study was to compare length of stay (LOS) between patients 
diagnosed with de-novo AML and patients diagnosed with AML with underlying MDS at 
Dekalb Medical Center. Studies on colorectal cancer have indicated that patients who 
received blood transfusions prior to surgery had a longer length of stay in the hospital.22 
Since length of stay can be influenced by multiple factors such as blood transfusion 
requirements and neutropenic fever, the association of these predictors to length of 
stay/time-to-discharge was evaluated in each disease group. Understanding the predictors 
of length of stay and comparing length of stay between groups during initial induction 
therapy will allow for a reduction in costs and an improvement in the quality of care for 
AML patients. This study can generate more information on AML patients with and 
without underlying MDS in order to improve clinical outcomes, quality of life, and costs 
in a community hospital setting.  
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STUDY QUESTIONS 
This study addressed these questions: 
Are patients diagnosed with de-novo AML more likely to have a complete remission 
compared to patients diagnosed with AML with underlying MDS?  
Are patients diagnosed with AML with underlying MDS more likely to have a longer 
length of stay/time-to-discharge compared to patients diagnosed with de-novo AML? 
Are the following predictors (age at diagnosis, number of chromosomal abnormalities) 
associated with remission status in each disease group?  
 Are these predictors (blood transfusion requirements, neutropenic fever) associated with 
length of time/time-to-discharge in each disease group?  
 
THESIS STATEMENT 
Patients at Dekalb Medical who are diagnosed with AML with underlying MDS will have 
a poorer prognosis (lower remission rates) compared to patients diagnosed with de-novo 
AML. Patients at Dekalb Medical who are diagnosed with AML with underlying MDS will 
have a longer length of stay (LOS) compared to patients who are diagnosed with de-novo 
AML due to an increased risk of infection and more blood transfusion requirements. 
 
 
STUDY POPULATION 
 
 This study initially recruited 52 patient participants. The study population was recruited 
using the following inclusion and exclusion criteria: The inclusion criteria were that study 
participants must be 18 years old or over, have been diagnosed with AML without MDS, 
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and received outpatient or inpatient care at Dekalb Medical Center. The exclusion criteria 
are that patients should be diagnosed with either APL (Acute Promyelocytic Leukemia) or 
ALL (Acute Lymphoblastic Leukemia). APL a subtype of AML that can be treated with a 
very specific treatment approach and is characterized by specific cytogenetic 
abnormalities. Due to good treatment outcomes, APL is considered to be the most curable 
type of leukemia with a 90% cure rate. Due to a more favorable prognosis, patients with 
this disease subtype will be excluded from this study.18 ALL (Acute Lymphoblastic 
Leukemia) is a cancer that affects lymphocytes, a premature version of white blood cells, 
in the bone marrow. In individuals with ALL, immature lymphoblasts tend to multiple and 
build up in the bone marrow, therefore preventing the production of other blood cells. ALL 
is more common in children and elderly adults. Due to a different etiology and more 
favorable prognosis, patients with ALL will be excluded from this study. The 
transformation of MDS to ALL is also extremely rare.19, 20, 21. The study analyzed 48 patient 
participants due to difficulties in obtaining medical records before 2002.  
 
METHODS 
This study was a retrospective chart review. In this type of study design, pre-recorded, 
entered data was used to answer the research question. The data was obtained using Sunrise 
Gateway, Sovera online medical databases, physician progress notes, cytogenetic reports, 
and pathology reports. The study was conducted at Dekalb Medical Center, a community 
hospital located in Decatur, GA. All information was de-identified through the online 
database and all guidelines in regards to HIPAA were followed. The following 
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demographic information was collected using these databases: date of birth, age at 
diagnosis, gender, ethnicity/race, insurance information, medical record number. The 
following clinical information was collected using these databases: disease type, treatment 
regimen, treatment complications, date of hospital admission, date of hospital discharge, 
blood transfusion requirements, prophylactic antibiotic use, and chromosomal 
abnormalities. For information that was not available, thorough data searches through the 
Cancer Registry databases were conducted. All of the data was organized into an Excel 
spreadsheet so that the appropriate statistical analyses could be conducted.
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STATISTICAL ANALYSES 
 
The Chi-Square Test was used to compare the relationship between categorical variables 
in the data set used in the study. The observed data had been counted or divided into 
categories as opposed to structuring the data on a continuous scale. In this study, the Chi-
Square Test was used to assess the following in relation to remission status:  
1a) To compare the remission rates between patients with de-novo AML and patients with 
AML with underlying MDS  
1b) To evaluate the association between age at diagnosis and remission status in patients 
with de-novo AML  
1c) To evaluate the association between age at diagnosis and remission status in patients 
with AML with underlying MDS  
1d) To evaluate the association between the number of chromosomal abnormalities and 
remission status in patients with de-novo AML  
1e) To evaluate the association between the number of chromosomal abnormalities and 
remission status in patients with AML with underlying MDS  
 
The Chi-Square Test and Kaplan-Meier Analysis were used to assess the effect of predictor 
variables (blood transfusion requirements and neutropenic fever) on the length of 
stay/time-to-discharge in each disease group. The Kaplan-Meier Analysis estimates the 
population survival for the study sample and to assess whether the data generated can be 
generalized to the overall population. A Kaplan-Meier analysis assesses the estimation of 
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survival over time, even when patients drop out of the study or the data is conducted over 
a long period of time. This indicates that subjects may not have had the opportunity to have 
the event of interest by the end of the follow-up period. Survival between groups can be 
compared and assessed in relation to the general population. While Kaplan-Meier is usually 
used to study mortality, in this study, the survival variable (length of stay) will be analyzed 
as a “time to discharge” variable. The “survival proportion” will be described as the chance 
of effectiveness of the intervention at that particular point in time in this time-to-event 
analysis. In this study, the following was evaluated in relation to length of stay:  
2a) To compare the length of stay (days) between patients with de-novo AML and patients 
with AML with underlying MDS (Chi-Square Test)  
2b) To compare length of stay (days) between patients diagnosed with de-novo AML and 
patients diagnosed with AML with underlying MDS (Kaplan-Meier) 
2c) To evaluate the effect of blood transfusion requirements on length of stay/time-to- 
discharge (days) in patients diagnosed with de-novo AML 
2d) To evaluate the effect of blood transfusion requirements and length of stay/time-to-
discharge (days) in patients diagnosed with AML with underlying MDS.  
2e) To evaluate the effect of neutropenic fever on the length of stay/time to discharge 
(days) in patients diagnosed with de-novo AML 
2f) To evaluate the effect of neutropenic fever on the length of stay/time to charge (days) 
in patients diagnosed with AML with underlying MDS  
The data was analyzed using XLSTAT statistical software, Excel, and R statistical 
software. The statistical methods that were used in this study include the following:  the  
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Chi-Square test, the Kaplan-Meier Analysis, the Log-Rank test, the Wilcoxon test, and the 
Tarone-Ware Test.  
 
RESULTS 
 		
A total of 48 patients were analyzed in this study, out of which 39 (81.25%) were diagnosed 
with de-novo AML and 9 (18.75%) were diagnosed with AML with underlying MDS. 
Table 1 describes the genders, sex, race, medical insurance and treatment requirements 
found in the study population. This table gives an overview of the clinical and demographic 
characteristics of the study population.  
 
Characteristics Level n % 
Gender Male 22 45.83 
 Female 26 54.17 
 
Age at Diagnosis 18-40 6 12.50 
 41-59 15 31.25 
 60 and over 27 56.25 
    
Race African 
American 
21 43.75 
 Caucasian 27 56.25 
 
    Medical Insurance Medicare 14 29.17 
 Medicaid 4 8.33 
 Private Pay 6 12.50 
 Blue Cross, 
Aetna Humana, 
Champra, 
Coventry 
24 50.00 
    
       Disease Groups  De-Novo AML 39 81.25 
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AML with 
MDS 
9 
 
 
 
         
 
 
 
18.75 
 
 
 
 
 
 
 
 
 
 
Treatment 
Regimens 
 
 
         
 
Anthracycline-
Based Therapy 
 
Demethylating 
Agents 
 
Antibody-Based 
Therapy 
          
               42  
 
 
                5 
 
 
                1 
 
          
                    87.50  
 
 
                    10.42 
 
 
                     2.08 
Table 1. Demographic and Clinical Characteristics of Study Population 
 
 
Remission Rates Analysis: Chi-Square Test:   
 
The primary objective of this study was assessed using the chi-square test. The primary 
objective was to compare remission rates between patients diagnosed with de-novo AML 
and patients diagnosed with AML with underlying MDS. The association of predictor 
variables (age at diagnosis and number of chromosomal abnormalities) was assessed in 
each disease group.  
 
1a) The chi square test was used to compare the remission rates between patients diagnosed 
with de-novo AML and patients diagnosed with AML with underlying MDS. The two 
categorical variables examined in this scenario included: disease type (de-novo AML or 
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AML with underlying MDS) and remission status (complete remission achieved or 
complete remission not achieved) The Null Hypothesis (H0) was that there was no 
association between disease type and remission status. The proportion of patients who 
achieved complete remission was independent of disease type. The Alternative Hypothesis 
(HA) was that there was an association between disease type and remission status. The 
proportion of patients who achieved complete remission was associated with disease type. 
More information regarding the remission rates across both disease groups can be found in 
the table 2a shown below.  
Remission 
Status 
 
De-Novo AML 
 
AML with 
MDS 
 
Total 
 
P-Value 
Complete 
Remission 
Achieved 
20 patients 3 patients 23 0.3312769 
 
Complete 
Remission 
Not Achieved 
19 patients 6  patients 25  
Total 39 patients 9  patients 48  
Table 2a. Comparison of Remission Rates Between Patients with De-Novo AML and 
Patients with AML with MDS  
 
As shown above, there were 20 patients (86.96%) who achieved complete remission in the 
de-novo AML group and 3 patients (13.04%) achieved complete remission in the AML 
with underlying MDS group. There were 19 patients (76%) who did not achieve complete 
remission in the de-novo AML group and 6 patients (24%) who did not achieve complete 
remission in AML with underlying MDS group. A higher percentage of patients diagnosed 
with de-novo AML (51%) achieved complete remission compared to patients diagnosed 
	 14	
with AML with underlying MDS. (33%) 0.9439 was the x2 value that was obtained using 
this test. Inputing this information along with the degrees of freedom value (df =1), the R 
software was able to generate a specific p-value using the following code: 
pchisq(0.9439,1). The p-value that was generated is shown in table 2 shown below. Since 
the value obtained (0.3312769) was greater than p = 0.05, there is no statistical significance 
in terms of the data. In this scenario, it is appropriate to fail to reject the null hypothesis. 
There is no association and statistically significant difference in remission rates between 
patients diagnosed with de-novo AML and patients diagnosed with AML with underlying 
MDS. The proportion of patients who achieved complete remission was independent of 
disease type. Therefore, the patients diagnosed with de-novo AML are not more likely to 
achieve complete remission in comparison to patients diagnosed with AML with 
underlying MDS.  
 
1b) The chi square test was used to evaluate the association between age at diagnosis and 
remission status in patients diagnosed with de-novo AML. The two categorical variables 
examined in this scenario included: age at diagnosis (18-50) or (>50) and remission status 
(complete remission achieved or complete remission not achieved) AML usually occurs in 
adults over the age of 45. However, due to the fact that the subjects in this study sample 
fall in the >50 age range, age 50 has been chosen as a cut-off for the chi-square test. The 
Null Hypothesis (H0) was that there was no association between age at diagnosis and 
remission status in patients diagnosed with de-novo AML. The proportion of patients who 
achieved complete remission was independent of age at diagnosis. The Alternative 
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Hypothesis (HA) was that there was an association between age at diagnosis and remission 
status in patients diagnosed with de-novo AML. The proportion of patients who achieved 
complete remission was associated with age at diagnosis. More information regarding the 
distribution of ages at diagnosis within this group is shown in the table 2b below:  
 
 
Remission Status 
 
Age at Dx (18-
50)  
 
Age at Dx 
(>50)  
 
Total  
 
p-Value  
Complete 
Remission 
Achieved 
 
12 
 
 
8 
 
20 
 
0.075  
Complete 
Remission Not 
Achieved 
 
6 
 
13 
 
19 
 
Total  
18 
 
21  
 
39 
 
Table 2b. Association between Age at Diagnosis and Remission Status – De-Novo AML 
 
As shown above, there were 12 patients (60%) in the (18-50) years old age range that 
achieved complete remission and 8 patients (40%) in the (>50) year old age range that 
achieved complete remission. There were 6 patients (31.58%) in the (18-50) year old age 
range that did not achieve complete remission and 13 patients (68.42%) in the (>50) year 
old range that did not achieve complete remission. 3.1699 was the x2 value that was 
obtained using this test. Inputing this information along with the degrees of freedom value 
(df =1), the R software was able to generate a specific p-value using the following code: 
pchisq(3.1699,1). The p-value that was generated is shown in table 2 shown below. Since 
the value obtained (0.075) is between 0.05 and 0.1, this result is marginally significant. In 
this scenario, it is appropriate to fail to reject the null hypothesis. There is a an association 
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between age at diagnosis and remission status, but it is not very strong in patients diagnosed 
with de-novo AML. This association indicates that perhaps younger patients could be more 
likely to benefit from therapy and achieve complete remission. However, a larger sample 
size would be required to illustrate a clearer association between age at diagnosis and 
remission status in patients diagnosed with de-novo AML and to confirm this finding.  
 
1c) The chi square test was used to evaluate the association between age at diagnosis and 
remission status in patients diagnosed with AML with underlying MDS. The two 
categorical variables examined in this scenario included: age at diagnosis (50-70) or (>70) 
and remission status (complete remission achieved or complete remission not achieved) 
AML usually occurs in adults over the age of 45. However, due to the fact that the subjects 
in this study sample fall in the >50 age range, age 50 has been chosen as a cut-off for the 
chi-square test. The Null Hypothesis (H0) was that there was no association between age 
at diagnosis and remission status in patients diagnosed with AML with underlying MDS. 
The proportion of patients who achieved complete remission was independent of age at 
diagnosis. The Alternative Hypothesis (HA) was that there was an association between age 
at diagnosis and remission status in patients diagnosed with AML with underlying MDS. 
The proportion of patients who achieved complete remission was associated with age at 
diagnosis. More information regarding the distribution of age at diagnoses within this 
group is shown in the table 2c below: 
Remission 
Status 
Age at 
Diagnosis (50-
70) 
Age at 
Diagnosis  (>70) 
 
Total 
 
P-Value  
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Complete 
Remission 
Achieved 
3 patients 0 patients 3 0.017706 
Complete 
Remission 
Not Achieved 
1 patient 5  patients 6  
Total 4 patients 5 patients 9  
Table 2c. Association between Age at Diagnosis and Remission Status – AML with 
MDS  
 
As shown above, there were 3 patients (100%) in the (50-70) years old age range that 
achieved complete remission and none of the patients in the (>70) year old age range that 
achieved complete remission. There was 1 patient (16.67%) in the (50-70) year old age 
range that did not achieve complete remission and 5 patients (83.33%) in the (>50) year 
old range that did not achieve complete remission. 5.625 was the x2 value that was obtained 
using this test. Inputing this information along with the degrees of freedom value (df =1), 
the R software was able to generate a specific p-value using the following: pchisq(5.625,1). 
The p-value that was generated is shown in table 2 shown below. Since the value obtained 
(0.017706) was less than p = 0.05, there is a statistical significance in terms of the data. In 
this scenario, it is appropriate to reject the null hypothesis. There is an association between 
age at diagnosis and remission status in patients diagnosed with AML with underlying 
MDS. This association indicates that older patients with AML with MDS are less likely to 
benefit from therapy and achieve complete remission.  
 
1d) The chi square test was used to evaluate the association between the number of 
chromosomal abnormalities and remission status in patients diagnosed with de-novo AML. 
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There are many types of chromosomal changes that are possible in this disease. The 
categorical variables that was used include the following: no chromosomal abnormalities 
(normal karyotype), 1 type of chromosomal abnormality, and more than one (>1) 
chromosomal abnormality. The Null Hypothesis (H0) was that there was no association 
between the number of chromosomal abnormalities and remission status in patients 
diagnosed with de-novo AML. The proportion of patients diagnosed with de-novo AML 
who achieved complete remission is independent of the number of chromosomal 
abnormalities they have. The Alternative Hypothesis (HA) was that there was an association 
between the number of chromosomal abnormalities and remission status in patients 
diagnosed with de-novo AML. The proportion of patients diagnosed with de-novo AML 
who achieved complete remission is associated with the number of chromosomal 
abnormalities they have. More information regarding the distribution of chromosomal 
abnormalities within this group is shown  in the table 2d below: 
Remission 
Status 
Normal 
Karyotype 
One 
Chromosomal 
Abnormality 
More than 
One (>1) 
Chromosomal 
Abnormality 
 
Total 
 
P-Value  
Complete 
Remission 
Achieved 
10 patients 4 patients 5 patients 19 0.87989
74 
Complete 
Remission 
Not Achieved 
11 patients 3 patients 6  patients 20  
Total 21 patients 7 patients 11 patients 39  
Table 2d. Association between Number of Chromosomal Abnormalities and Remission 
Status – De-Novo AML  
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As shown above, there were 10 patients who had a normal karyotype and did achieve 
complete remission. There were 4 patients who each had 1 chromosomal abnormality and 
achieved complete remission. There were 5 patients who each had more than 1 
chromosomal abnormality and achieved completer remission. There were 11 patients who 
had a normal karyotype and did not achieve complete remission. There were 3 patients who 
each had 1 chromosomal abnormality and did not achieve complete remission. There were 
6 patients who each had more than 1 chromosomal abnormality and did not achieve 
complete remission. 0.2559 was the x2 value obtained using this test. Inputing this 
information along with the degrees of freedom value (df=2), the R software was able to 
generate a specific p-value using the following: pchisq(0.2559, 2). Since the value obtained 
(0.8798974) is greater than a p value = 0.05, there is no statistical significant difference in 
terms of the data. In this scenario, it is appropriate to fail to reject the null hypothesis. There 
is no association between the number of chromosomal abnormalities and remission status 
in patients diagnosed with de-novo AML.  The proportion of patients diagnosed with de-
novo AML who achieved complete remission is independent of the number of 
chromosomal abnormalities they have.  
 
1e) The Chi-Square was also used to evaluate the association between the number of 
chromosomal abnormalities and remission status in patients diagnosed with AML with 
underlying MDS. There are many chromosomal changes that are possible in this disease. 
The categorical variables that were used in this analysis include the following: no 
chromosomal abnormalities (normal karyotype, one chromosomal abnormality, and more 
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than one chromosomal abnormality. The Null Hypothesis (H0) was that there was no 
association between the number of chromosomal abnormalities and remission status in 
patients diagnosed with AML with underlying MDS. The proportion of patients diagnosed 
with AML with underlying MDS who achieved complete remission is independent of the 
number of chromosomal abnormalities thy have. The Alternative Hypothesis (HA) was that 
there was an association between the number of chromosomal abnormalities and remission 
status in patients diagnosed with AML with underlying MDS. The proportion of patients 
diagnosed with AML with underlying MDS who achieved complete remission is 
associated with the number of chromosomal abnormalities they have. More information 
regarding the distribution of number of chromosomal abnormalities within this group is 
shown in the table 2e below: 
Remission 
Status 
Normal 
Karyotype 
One 
Chromosomal 
Abnormality 
More than 
One (>1) 
Chromosomal 
Abnormality 
 
Total 
 
P-Value  
Complete 
Remission 
Achieved 
1 patient 1 patient 1 patient 3 0.0764246 
Complete 
Remission 
Not Achieved 
 6 patients 0 patients 0 patients 6  
Total 7 patients 1 patient 1 patient 9  
Table 2e. Association between Number of Chromosomal Abnormalities and Remission 
Status – AML with MDS  
 
As shown above, there was 1 patient (33.33%) who had a normal karyotype and did achieve 
complete remission. There was 1 patient (33.33%) who had 1 chromosomal abnormality 
and achieved complete remission. There was 1 patient (33.33%) who had more than 1 
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chromosomal abnormality and achieved complete remission. There were 6 patients (100%) 
who had a normal karyotype and did not achieve complete remission. There were 0 patients 
(0%) who had 1 chromosomal abnormality and did not achieve complete remission. There 
were 0 patients (0%) who had more than 1 chromosomal abnormality and did not achieve 
complete remission. 5.1429 was the x2 value obtained using this test. Inputing this 
information along with the degrees of freedom value (df=2), the R software was able to 
generate a specific p-value using the following code: pchisq(5.1429, 2). Even though the 
value obtained (0.0764246) is greater than a p value = 0.05, there is a marginally 
statistically significant difference in terms of the data. There is a weak association between 
the number of chromosomal abnormalities and remission status in patients diagnosed with 
AML with underlying MDS. This association indicates that patients with AML with 
underlying MDS with one or more chromosomal abnormalities could be more likely to 
benefit from therapy and achieve complete remission. However, a larger sample size will 
be required to show a clearer association between these variables and to confirm this 
finding.  
 
Length of Stay (LOS) Analysis: Chi-Square Test and Kaplan-Meier Analysis  
The secondary objective of this study was also assessed using the chi-square test and 
Kaplan-Meier Analysis. The secondary objective was to compare length of stay between 
disease groups. Following this, the association of predictor variables (blood transfusion 
types and neutropenic fever) was assessed in each disease group using the Kaplan-Meier 
Analysis.  
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2a) The length of stay (days) between patients diagnosed with de-novo AML and patients 
diagnosed with AML with underlying MDS was compared using the Chi-Square Test. The 
categorical variables used in this analysis included the following: Disease Type (De-novo 
AML or AML with underlying MDS) and Length of Stay (days). The following length of 
stay ranges were used: 0-20 days, 21-35 days, and > 35 days due to the fact that most 
patients need to stay in the hospital for 3 to 5 weeks during induction therapy.4 The Null 
Hypothesis (H0) was that there was no association between the length of stay (days) and 
disease type (de-novo AML or AML with underlying MDS). The Alternative Hypothesis 
(HA) was that there was an association between the length of stay (days) and disease type 
(de-novo AML or AML with underlying MDS). More information regarding the analysis 
is shown in the table 2f below:  
Disease Group 0-20 days  21- 35 days > 35 days  
Total 
 
P-Value  
De-Novo AML 9 patients 25  patients 5 patients 39 0.29053 
AML with MDS  4 patients 5 patients 0 patients 9    
Total 13 patients 30 patients 5 patients 48  
Table 2f. Comparison of Length of Stay (days) between Patients with De-Novo AML and 
Patients with AML with MDS 
 
As shown above, there were 9 patients (23.08%) who had a length of stay between 0-20 
days in the de-novo AML group. There were 25 patients (64.10%) who had a length of stay 
between 18-35 days in the de-novo AML group. There were 5 patients (12.82%) who had 
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a length of stay of greater than 35 days in the de-novo AML group. There were 4 patients 
(44.44%) who had a length of stay between 0-20 days. There were 5 patients (55.56%) who 
had a length of stay between 21-35 days. There were 0 patients (0%) who had a length of 
stay greater than 35 days. 2.4721 was the x2 value obtained using this test. Inputing this 
information along with the degrees of freedom value (df=2), the R software was able to 
generate a specific p-value using the following code: pchisq(2.4721, 2). Since the value 
obtained (0.29053) is greater than a p value = 0.05, there is no statistical significant 
difference in terms of the data. In this scenario, it is appropriate to fail to reject the null 
hypothesis. There is no significant difference in length of stay (days) between patients who 
are diagnosed with de-novo AML and patients who are diagnosed with AML with MDS. 
The proportion of patients who had a longer length of stay (days) was independent of 
disease type.  
 
 
 
 
Length-of-Stay Analysis:  
 
The Kaplan-Meier Analysis was used to compare the time-to-discharge (days) between 
patients diagnosed with de-novo AML and patients diagnosed with AML with underlying 
MDS in this study population. This method was also used to evaluate the effect of certain 
interventions/predictor variables on the time-to-discharge in each disease group. In this 
study, the interventions/predictor variables that were examined include the following: 
blood transfusion requirements and neutropenic fever. On each graph, the survival 
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probability (%) describes the chance of effectiveness of the intervention of interest rather 
than the overall chance of survival for each individual patient in this time-to-event analysis. 
The analysis estimated the effectiveness of such an intervention in population for the study 
sample and assessed whether the results obtained could be generalizable to the overall 
population, even when patients dropped out of the study or died for other unknown reasons.  
	
Kaplan-Meier Analysis #1: 
Time-To-Discharge (Disease Group)  
De-Novo AML vs. AML with MDS.  
	
2b) The Kaplan-Meier Method was used to compare the time-to-discharge (days) between 
patients diagnosed with de-novo AML and patients diagnosed with AML with underlying 
MDS. The two groups that were compared in this analysis included the following: Stratum 
1 – Patients diagnosed with de-novo AML; Stratum 2 – Patients diagnosed with AML with 
underlying MDS. The Status Variable was indicated as the following: 1 – Patients who 
were discharged; 0 – Patients who either withdrew from the study or died for unknown 
reasons. The time variable was indicated as the time-to-discharge (days) or the number of 
days the patient remained in the hospital. The Null Hypothesis (H0) was that there was no 
difference in time-to-discharge (days) between patients diagnosed with de-novo AML and 
patients diagnosed with AML with underlying MDS. The Alternative Hypothesis (Ha) was 
that there was a difference in time-to-discharge (days) between patients diagnosed with de-
novo AML and patients diagnosed with AML with underlying MDS. The mean time-to-
discharge (days) was calculated for each group and is illustrated in the table 3a below:  
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Stratum # Mean Time-To-Discharge 
(days) 
Stratum 1 –  De-Novo AML  26.410  
Stratum 2 – AML with MDS  22.536  
Table 3a. Mean Time-To-Discharge (Days) – De-Novo AML and AML with MDS  
 
As shown in the table above, the mean time-to-discharge (days) varied across the two 
groups observed in this analysis. Of the two groups, patients diagnosed with de-novo AML 
had a higher mean time-to-discharge (26.410 days) compared to patients diagnosed with 
AML with underlying MDS. (22.536 days) The graphs to follow illustrate the chance of 
patient response to treatment (%) in relation to time-to-discharge (days). 
Graph 1a. Survival Distribution Function: Length of Stay - Patients with De-Novo AML  
 
On Graph 1a shown above, the x-axis describes the time-to-discharge (days) and the y-axis 
describes the chance of patient response (%) to treatment. At a time-to-discharge of 6 days, 
the patient response to treatment for de-novo AML was 95%. At a time-to-discharge of 49 
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days, the chance of patient response to treatment for de-novo AML was 0.026%. This graph 
illustrates that as the time-to-discharge (days) increases, the chance of patient response to 
treatment decreases. The higher chance of patient response to treatment, the less time (days) 
that patients diagnosed with de-novo AML are required to stay in the hospital.  
Graph 1b. Survival Distribution Function: Length of Stay: Patients with AML with MDS 
 
On Graph 1b shown above, the x-axis describes the time-to-discharge (days) and the y-axis 
describes the chance of patient response (%) to disease. At a time-to-discharge of 7 days, 
the patient response to AML with underlying MDS was 88%. At a time-to-discharge of 30 
days, the chance of patient response to AML with MDS was 0.00%. This graph illustrates 
that as the time-to-discharge (days) increases, the chance of patient response decreases. 
The higher chance of patient response to disease, the less time (days) that patients 
diagnosed with de-novo AML are required to stay in the hospital.  
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Graph 1c. Survival Distribution Function: Time-To-Discharge for De-Novo AML and 
AML with MDS  
 
On Graph 1c shown above, the x-axis describes the time-to-discharge (days) and the y-axis 
describes the chance of patient response to disease. The blue curve represents patients 
diagnosed with de-novo AML. The green curve represents patients diagnosed with AML 
with underlying MDS. The blue curve (1) has a wider range and a higher mean time-to-
discharge value compared to the green curve, indicating that patients in this group were 
discharged after a longer period of time. Whether these differences in time-to-discharge 
(days) between disease groups are due to poorer prognosis or treatment complications is 
unknown.  
To determine whether these differences (shown above) in time-to-discharge (days) 
between disease groups were statistically significant and generalizable to the overall 
population, three comparison tests were conducted. The Log-Rank Test, The Wilcoxon 
Test, and the Tarone-Ware Tests were performed to determine whether these differences 
were significant, and if so, where are they significant. The Log-Rank test (table 3b) was 
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performed to demonstrate whether these differences were significant later in time. The 
Wilcoxon test (table 3b) was performed to demonstrate whether these differences were 
significant earlier in time. The Tarone-Ware test (table 3b) was performed to demonstrate 
whether these differences were significant in the time in between. The Null Hypotheses 
(H0) included the following: There were no differences in time-to-discharge (days) between 
the four groups compared in this analysis in the long-term, short term, and in between. The 
Alternative Hypotheses (Ha) included the following: There were differences in the time-to-
discharge (days) between the four groups compared in this analysis in the long term, short 
term, and in between.  
 
Statistic Observed Value Critical value p-value alpha 
Log-rank 1.921 3.841 0.166 0.050 
Wilcoxon 0.975 3.841 0.324 0.050 
Tarone-Ware 1.342 3.841 0.247 0.050 
Table 3b. Comparison Tests for Kaplan-Meier Analysis #1  
 
Log-Rank Test: 
Since the value obtained (0.166) is greater than the alpha value of 0.05, it was determined 
that there was no statistical significant difference in time-to-discharge (days) between the 
two groups compared in the long term. Therefore we fail to reject the null hypothesis. There 
is no statistically significant difference in time-to-discharge (days) between patients 
diagnosed with de-novo AML and patients diagnosed with AML with underlying MDS.  
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Wilcoxon Test: 
Since the value obtained (0.324) is greater than the alpha value of 0.05, it is determined 
that there is no statistically significant difference in time-to-discharge (days) between the 
two groups compared in the short term. Therefore, it is appropriate to fail to reject the null 
hypothesis. There is no statistically significant difference in time-to-discharge (days) 
between patients diagnosed with de-novo AML and patients diagnosed with AML with 
underlying MDS.  
Tarone-Ware Test: 
Since the value obtained (0.247) is greater than the alpha value of 0.05, it is determined 
that there is no statistically significant difference in time-to-discharge (days) between the 
two groups compared in the time in between. Therefore, it is appropriate to fail to reject 
the null hypothesis. There is no statistically significant difference in time-to-discharge 
(days) between patients diagnosed with de-novo AML and patients diagnosed with AML 
with underlying MDS.  
The curves are not statistically significant based on their difference. Since there is no 
statistically significant difference, it cannot be concluded that the chances of patient 
response to the disease (%) examined are different from the overall population. Therefore, 
this means that the results obtained are reflective of differences in the overall population, 
and are therefore generalizable. The differences shown in the time-to-discharge (days) 
between two groups compared in this analysis was not statistically significant.   
There were no statistically significant differences found in time-to-discharge (days) 
between disease groups.  
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Kaplan-Meier Analysis #2 Results:   
Blood Transfusion Requirements (De-Novo AML)  
	
2c) The Kaplan-Meier Analysis was used to examine the effect of blood transfusion 
requirements on the time-to-discharge (days) in patients diagnosed with de-novo AML. 
The four groups that were compared in this analysis included the following: Stratum 1 – 
Patients who received both red blood cell (RBC) and platelet transfusions; Stratum 2 – 
Patients who received only platelet transfusions; Stratum 3 – Patients who received only 
red blood cell (RBC) transfusions; Stratum 4 – Patients who did not received any blood 
transfusions. The Status Variable was indicated as the following: 1 – Patients who were 
discharged; 0 – Patients who either withdrew from the study or died for unknown reasons. 
The time variable was indicated as the time-to-discharge (days) or the number of days the 
patient remained in the hospital. The Null Hypothesis (H0) was that there was no difference 
in time-to-discharge (days) between the four groups of de-novo AML patients based on the 
type of blood transfusion requirements used. The Alternative Hypothesis (Ha) was that 
there was a difference in time-to-discharge (days) between the four groups of de-novo 
AML patients based on the type of blood transfusion requirements. The mean time-to-
discharge (days) was calculated for each group and is illustrated in the table 3c below:  
Stratum # Mean Time-To-Discharge 
(days) 
Stratum 1 – RBC/Platelet 27.517 
Stratum 2 – Platelet Only 21.000 
Stratum 3 – RBC Only 22.000 
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Stratum 4 – No Transfusions 26.000 
Table 3c. Blood Transfusion Requirements and Mean Time-To-Discharge (Days) – De-
Novo AML  
 
As shown in the table 3c above, the mean time-to-discharge (days) varied across the four 
groups observed in this analysis. Of all four groups, patients receiving red blood cell (RBC) 
and platelet transfusions had the highest mean time-to-discharge (27.517 days) and patients 
receiving only platelet transfusions had the lowest mean time-to-discharge (21.000 days). 
The graphs to follow illustrate the effectiveness of each blood transfusion requirement in 
relation to time-to-discharge (days).  
 
Graph 2a. Survival Distribution Function: Patients with De-Novo AML – RBC & Platelet 
Blood Transfusions 
 
On Graph 2a shown above, the x-axis describes the time-to-discharge (days) and the y-axis 
describes the chance of effectiveness (%) of red blood cell (RBC) and platelet transfusion 
regimen for patients diagnosed with de-novo AML. At a time-to-discharge of 6 days, the 
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chance of effectiveness of the red blood cell (RBC) and platelet blood transfusion 
requirement was 93% in a patient diagnosed with de-novo AML. At a time-to-discharge of 
49 days, the chance of effectiveness of the red blood cell (RBC) and platelet blood 
transfusion requirement was 0.034% in a patient diagnosed with de-novo AML. This graph 
illustrates that as the time-to-discharge (days) increases, the chance of effectiveness (%) of 
the blood transfusion requirement decreases. The higher chance of effectiveness for the 
blood transfusion, the less time (days) that patients diagnosed with de-novo AML are 
required to stay in the hospital.  
 
 
Graph 2b. Survival Distribution Function: Patients with De-Novo AML – Platelet Blood 
Transfusions Only  
 
On Graph 2b shown above, the x-axis describes the time-to-discharge (days) and the y-axis 
describes the chance of effectiveness (%) of platelet blood transfusion requirement for 
patients diagnosed with de-novo AML. At a time-to-discharge of 8 days, the chance of 
effectiveness of the platelet blood transfusion regimen was 75% in a patient diagnosed with 
de-novo AML. At a time-to-discharge of 26 days, the chance of effectiveness of the platelet 
blood transfusion requirement was 0.00% in a patient diagnosed with de-novo AML. This 
0
0.5
1
0 5 10 15 20 25 30
Time to Discharge
Survival distribution function (2)
	 33	
graph illustrates that as the time-to-discharge (days) increases, the chance of effectiveness 
(%) of the blood transfusion requirement decreases. The higher chance of effectiveness for 
the blood transfusion, the less time (days) that patients diagnosed with de-novo AML are 
required to stay in the hospital. For this graph, the range of time-to-discharge values is 
much smaller, indicating that patients receiving only platelet blood transfusions require 
less time in the hospital compared to those receiving red blood cell and platelet 
transfusions. Whether this is due to better disease prognosis or less treatment complications 
is unknown.  
 
Graph 2c. Survival Distribution Function: Patients with De-Novo AML –Red Blood Cell 
Transfusions Only 
 
On Graph 2c shown above, the x-axis describes the time-to-discharge (days) and the y-axis 
describes the chance of effectiveness (%) of RBC blood transfusion requirement for 
patients diagnosed with de-novo AML. At a time-to-discharge of 11 days, the chance of 
effectiveness of the platelet blood transfusion requirement was 50% in a patient diagnosed 
with de-novo AML. At a time-to-discharge of 33 days, the chance of effectiveness of the 
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platelet blood transfusion requirement was 0.00% in a patient diagnosed with de-novo 
AML. This graph illustrates that as the time-to-discharge (days) increases, the chance of 
effectiveness (%) of the blood transfusion requirement decreases. The higher chance of 
effectiveness for the blood transfusion, the less time (days) that patients diagnosed with 
de-novo AML are required to stay in the hospital. For this graph, the range of time-to-
discharge values is small, indicating that patients receiving only RBC blood transfusions 
require less time in the hospital. This range of values are less than those required for red 
blood cell and platelet transfusions and greater than those required for platelet only 
transfusions. Whether this is due to better disease prognosis or less treatment complications 
is unknown.  
 
Graph 2d. Survival Distribution Function: Patients with De-Novo AML – No Blood 
Transfusions 
 
On Graph 2d shown above, the x-axis describes the time-to-discharge (days) and the y-axis 
describes the chance of effectiveness (%) of RBC blood transfusion requirement for 
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patients diagnosed with de-novo AML. At a time-to-discharge of 21 days, the chance of 
effectiveness of receiving no blood transfusions was 25% in a patient diagnosed with de-
novo AML. At a time-to-discharge of 36 days, the chance of effectiveness of the platelet 
blood transfusion regimen was 0.00% in a patient diagnosed with de-novo AML. This 
graph illustrates that as the time-to-discharge (days) increases, the chance of effectiveness 
(%) of the blood transfusion requirement decreases. The higher chance of effectiveness for 
the blood transfusion, the less time (days) that patients diagnosed with de-novo AML are 
required to stay in the hospital. For this graph, the range of time-to-discharge values is 
smaller, than the range for patients receiving both red blood cell and platelet transfusions, 
indicating that those not receiving any blood transfusions require less time in the hospital. 
Whether this is due to better disease prognosis or less treatment complications is unknown.  
Graph 2e. Survival Distribution Function: Patients with De-Novo AML – Blood 
Transfusion Requirements 
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On Graph 2e shown above, the x-axis describes the time-to-discharge (days) and the y-axis 
describes the chance of effectiveness (%) of RBC blood transfusion requirement for 
patients diagnosed with de-novo AML. The blue curve represents patients diagnosed with 
de-novo AML who received red blood cell (RBC) and platelet blood transfusions. The 
green curve represents patients diagnosed with de-novo AML who received only platelet 
transfusions. The pink curve represents patients diagnosed with de-novo AML who 
received only red blood cell (RBC) blood transfusions. The orange curve represents 
patients diagnosed with de-novo AML who received no blood transfusions. It is important 
to note the differences between time-to-discharge (days) between the four curves shown in 
the graph. The blue curve (1) has a wider range and a higher mean time-to-discharge value 
compared to the other curves, indicating that patients in this group were discharged after a 
longer period of time. Whether the longer time-to-discharge (days) is due to poorer 
prognosis or treatment complications is unknown.  
To determine whether these differences (shown above) in time-to-discharge (days) 
between blood transfusion requirements were statistically significant and generalizable to 
the overall population, three comparison tests were conducted. The Log-Rank Test, The 
Wilcoxon Test, and the Tarone-Ware Tests were performed to determine whether these 
differences were significant, and if so, where are they significant. The Log-Rank test 
(table 3d) was performed to demonstrate whether these differences were significant later 
in time. The Wilcoxon test (table 3d) was performed to demonstrate whether these 
differences were significant earlier in time. The Tarone-Ware test (table 3d) was 
performed to demonstrate whether these differences were significant in the time in 
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between. The Null Hypotheses (H0) included the following: There were no differences in 
time-to-discharge (days) between the four groups compared in this analysis in the long-
term, short term, and in between. The Alternative Hypotheses (Ha) included the following: 
There were differences in the time-to-discharge (days) between the four groups compared 
in this analysis in the long term, short term, and in between.  
 
Table 3d. Comparison Tests for Kaplan-Meier Analysis #2  
 
Log Rank Test:  
Since the value obtained (0.224) is greater than the alpha value of 0.05, it was determined 
that there was no statistical significant difference in time-to-discharge (days) between the 
four groups compared in the long term. Therefore we fail to reject the null hypothesis. 
There is no difference in time-to-discharge (days) based on the types of blood transfusions 
obtained in group containing patients diagnosed with de-novo AML.  
Wilcoxon Test: 
Since the value obtained (0.352) is greater than the alpha value of 0.05, it is determined 
that there is no statistically significant difference in time-to-discharge (days) between the 
four groups compared in the short term. Therefore, it is appropriate to fail to reject the null 
hypothesis. There is no difference in time-to-discharge (days) based on the types of blood 
transfusions obtained in the group containing patients diagnosed with de-novo AML. 
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Tarone-Ware Test:  
Since the value obtained (0.287) is greater than the alpha value of 0.05, it is determined 
that there is no statistically significant difference in time-to-discharge (days) between the 
four groups compared in the time in between. Therefore, it is appropriate to fail to reject 
the null hypothesis. There is no difference in time-to-discharge (days) based on the types 
of blood transfusions obtained in the group containing patients diagnosed with de-novo 
AML. 
The curves are not statistically significant based on their difference. Since there is no 
statistically significant difference, it cannot be concluded that the chances of effectiveness 
(%) of the intervention examined are different from the overall population. Therefore, this 
means that the results obtained are reflective of differences in the overall population, and 
are therefore generalizable. The differences shown in the time-to-discharge (days) between 
four groups compared in this analysis was not statistically significant.  
 
Kaplan-Meier Analysis #3 Results: 
Blood Transfusion Requirements (AML with MDS)  
 
2d) The Kaplan-Meier Analysis was used to examine the effect of blood transfusion 
requirements on the time-to-discharge (days) in patients diagnosed with AML with 
underlying MDS. The two groups that were compared in this analysis included the 
following: Stratum 1 – Patients who received both red blood cell (RBC) and platelet 
transfusions; Stratum 2 – Patients who received only platelet transfusions. The Status 
Variable was indicated as the following: 1 – Patients who were discharged; 0 – Patients 
who either withdrew from the study or died for unknown reasons. The time variable was 
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indicated as the time-to-discharge (days) or the number of days the patient remained in the 
hospital. The Null Hypothesis (H0) was that there was no difference in time-to-discharge 
(days) between the two groups of patients diagnosed with AML with underlying MDS 
based on the type of blood transfusion requirements used. The Alternative Hypothesis (Ha) 
was that there was a difference in time-to-discharge (days) between the two groups of 
patients diagnosed with AML with underlying MDS based on the type of blood transfusion 
requirements used. The mean time-to-discharge (days) was calculated for each group and 
is illustrated in the table 3e below:  
Stratum # Mean Time-To-Discharge 
(days) 
Stratum 1 – RBC/Platelet 23.400 
Stratum 2 – Platelet ONLY 14.000 
Table 3e. Blood Transfusion Requirements and Mean Time-To-Discharge (Days) – AML 
with MDS  
 
As shown in the table above, the mean time-to-discharge (days) varied across the two 
groups observed in this analysis. Of the two groups, patients receiving red blood cell (RBC) 
and platelet transfusions had a higher mean time-to-discharge (23.400 days). The graphs 
to follow illustrate the effectiveness of each blood transfusion requirement in relation to 
time-to-discharge (days).  
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Graph 3a. Survival Distribution Function: Patients with AML with underlying MDS – 
RBC & Platelet Blood Transfusions  
 
On Graph 3a shown above, the x-axis describes the time-to-discharge (days) and the y-axis 
describes the chance of effectiveness (%) of red blood cell (RBC) and platelet transfusion 
requirement for patients diagnosed with AML with underlying MDS. At a time-to-
discharge of 7 days, the chance of effectiveness of the red blood cell (RBC) and platelet 
blood transfusion requirement was 100% in a patient diagnosed with AML with underlying 
MDS. At a time-to-discharge of 30 days, the chance of effectiveness of the red blood cell 
(RBC) and platelet blood transfusion regimen was 0.00% in a patient diagnosed with de-
novo AML. This graph illustrates that as the time-to-discharge (days) increases, the chance 
of effectiveness (%) of the blood transfusion requirement decreases. The higher chance of 
effectiveness for the blood transfusion, the less time (days) that patients diagnosed with 
de-novo AML are required to stay in the hospital.  
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Graph 3b. Survival Distribution Function: Patients with AML with underlying MDS – 
Platelet Blood Transfusions Only  
 
On Graph 3b shown above, the x-axis describes the time-to-discharge (days) and the y-axis 
describes the chance of effectiveness (%) of platelet blood transfusion requirement for 
patients diagnosed with de-novo AML. At a time-to-discharge of 14 days, the chance of 
effectiveness of the platelet blood transfusion requirement was 100% in a patient diagnosed 
with AML with underlying MDS. At a time-to-discharge of 14 days, the chance of 
effectiveness of the platelet blood transfusion requirement was 0.00% in a patient 
diagnosed with AML with underlying MDS. This graph illustrates that as the time-to-
discharge (days) increases, the chance of effectiveness (%) of the blood transfusion 
regimen decreases. The higher chance of effectiveness for the blood transfusion, the less 
time (days) that patients diagnosed with de-novo AML are required to stay in the hospital. 
For this graph, the range of time-to-discharge values is much smaller, due to the face that 
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there was only one patient in this group. The graph illustrates that patients receiving only 
platelet blood transfusions require less time in the hospital compared to those receiving red 
blood cell and platelet transfusions. Whether this is due to better disease prognosis or less 
treatment complications is unknown.  
 
 
Graph 3c. Survival Distribution Function: Patients with AML with MDS – Blood 
Transfusion Requirements  
 
On Graph 3c shown above, the x-axis describes the time-to-discharge (days) and the y-axis 
describes the chance of effectiveness (%) of RBC blood transfusion requirement for 
patients diagnosed with de-novo AML. The blue curve represents patients diagnosed with 
AML with underlying MDS who received red blood cell (RBC) and platelet transfusions 
and the green curve represents patients diagnosed with AML with underlying MDS who 
received only platelet blood transfusions. It is important to note the differences between 
time-to-discharge (days) between the two curves shown in the graph. The blue curve (1) 
has a wider range and a higher mean time-to-discharge value compared to the green curve, 
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indicating that patients in this group were discharged after a longer period of time. The last 
patient in each group was discharged at a different time, indicating that different blood 
transfusion requirements can affect the time-to-discharge (days). Whether the longer time-
to-discharge (days) is due to poorer prognosis or treatment complications is unknown. 
To determine whether these differences (shown above) in time-to-discharge (days) 
between blood transfusion requirements were statistically significant and generalizable to 
the overall population, three comparison tests were conducted. The Log-Rank Test, The 
Wilcoxon Test, and the Tarone-Ware Tests were performed to determine whether these 
differences were significant, and if so, where are they significant. The Log-Rank test 
(table 3f) was performed to demonstrate whether these differences were significant later in 
time. The Wilcoxon test (table 3f) was performed to demonstrate whether these differences 
were significant earlier in time. The Tarone-Ware test (table 3f) was performed to 
demonstrate whether these differences were significant in the time in between. The Null 
Hypotheses (H0) included the following: There were no differences in time-to-discharge 
(days) between the two groups compared in this analysis in the long-term, short term, and 
in between. The Alternative Hypotheses (Ha) included the following: There were 
differences in the time-to-discharge (days) between the two groups compared in this 
analysis in the long term, short term, and in between.  
Table 3f. Comparison Tests for Kaplan-Meier Analysis #3  
Log-Rank Test: 
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Since the value obtained (0.094) is greater than the alpha value of 0.05, it was determined 
that there was no statistical significant difference in time-to-discharge (days) between the 
two groups compared in the long term. Therefore we fail to reject the null hypothesis. There 
is no statistically significant difference in time-to-discharge (days) based on the types of 
blood transfusions obtained in group containing  patients diagnosed with AML with 
underlying MDS.  
Wilcoxon Test:  
Since the value obtained (0.121) is greater than the alpha value of 0.05, it is determined 
that there is no statistically significant difference in time-to-discharge (days) between the 
two groups compared in the short term. Therefore, it is appropriate to fail to reject the null 
hypothesis. There is no statistically significant difference in time-to-discharge (days) based 
on the types of blood transfusions obtained in the group containing patients diagnosed with 
AML with underlying MDS.  
Tarone-Ware Test:  
Since the value obtained (0.107) is greater than the alpha value of 0.05, it is determined 
that there is no statistically significant difference in time-to-discharge (days) between the 
two groups compared in the time in between. Therefore, it is appropriate to fail to reject 
the null hypothesis. There is no statistically significant difference in time-to-discharge 
(days) based on the types of blood transfusions obtained in the group containing patients 
diagnosed with AML with underlying MDS.  
The curves are not statistically significant based on their difference. Since there is no 
statistically significant difference, it cannot be concluded that the chances of effectiveness 
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(%) of the intervention examined are different from the overall population. Therefore, this 
means that the results obtained are reflective of differences in the overall population, and 
are therefore generalizable. The differences shown in the time-to-discharge (days) between 
two groups compared in this analysis was not statistically significant.   
While there were no statistically significant differences found in time-to-discharge (days) 
within each disease group, it is important to note the mean-to-discharge (days) was higher 
in patients with de-novo AML in comparison to patients with AML with underlying MDS.  
 
Kaplan-Meier Analysis Results #4: 
Neutropenic Fever (De-Novo AML)  
 
2e) The Kaplan-Meier Analysis was used to examine the effect of neutropenic fever on the 
time-to-discharge (days) in patients diagnosed with de-novo AML. The two groups that 
were compared in this analysis included the following: Stratum 1 – Patients who had 
neutropenic fever; Stratum 2 – Patients who did not have neutropenic fever. The Status 
Variable was indicated as the following: 1 – Patients who were discharged; 0 – Patients 
who either withdrew from the study or died for unknown reasons. The time variable was 
indicated as the time-to-discharge (days) or the number of days the patient remained in the 
hospital. The Null Hypothesis (H0) was that there was no difference in time-to-discharge 
(days) between the two groups of patients diagnosed with AML with underlying MDS 
based on the presence or absence of neutropenic fever. The Alternative Hypothesis (Ha) 
was that there was a difference in time-to-discharge (days) between the two groups of 
patients diagnosed with AML with underlying MDS based on the presence or absence of 
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neutropenic fever. The mean time-to-discharge (days) was calculated for each group and 
is illustrated in the table 3g below:  
Stratum # Mean Time-To-Discharge 
(days) 
Stratum 1 –  Neutropenic Fever  28.632 
Stratum 2 –  No Neutropenic Fever 24.300 
Table 3g. Neutropenic Fever and Mean Time-To-Discharge (Days) – De-Novo AML 
 
As shown in the table 3g above, the mean time-to-discharge (days) varied across the two 
groups observed in this analysis. Of the two groups, patients with neutropenic fever a 
higher mean time-to-discharge (28.632 days) than patients without neutropenic fever 
(24.300 days). The graphs to follow illustrate the effectiveness of neutropenic fever/ chance 
of patient response to neutropenic fever in relation to time-to-discharge (days) for patients 
diagnosed with de-novo AML.  
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Graph 4a. Survival Distribution Function: Patients with De-Novo AML – Neutropenic 
Fever  
 
On Graph 4a shown above, the x-axis describes the time-to-discharge (days) and the y-axis 
describes the chance of patient response (%) to neutropenic fever for patients diagnosed 
with de-novo AML. At a time-to-discharge of 11 days, the chance of effectiveness and 
patient response to neutropenic fever was approximately 94% in a patient diagnosed with 
de-novo AML. At a time-to-discharge of 49 days, the patient response to neutropenic fever 
was 0.053% in a patient diagnosed with de-novo AML. This graph illustrates that as the 
time-to-discharge (days) increases, the chance of patient response (%) to neutropenic fever 
decreases. The lower the patient response to neutropenic fever, the more time (days) that 
patients diagnosed with de-novo AML are required to stay in the hospital.  
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Graph 4b. Survival Distribution Function: Patients with De-Novo AML – No Neutropenic 
Fever  
 
On Graph 4b shown above, the x-axis describes the time-to-discharge (days) and the y-axis 
describes the chance of patient response (%) to the absence of neutropenic fever for patients 
diagnosed with de-novo AML. At a time-to-discharge of 6 days, the chance of patient 
response to the absence of neutropenic fever was approximately 90% in a patient diagnosed 
with de-novo AML. At a time-to-discharge of 40 days, the patient response to the absence 
of neutropenic fever was 0.05% in a patient diagnosed with de-novo AML. This graph 
illustrates that as the time-to-discharge (days) increases, the chance of patient response (%) 
to neutropenic fever decreases. The lower the patient response to neutropenic fever, the 
more time (days) that patients diagnosed with de-novo AML are required to stay in the 
hospital.  
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Graph 4c. Survival Distribution Function: Patients with De-Novo AML (Neutropenic 
Fever / No Neutropenic Fever)  
 
On Graph 4c shown above, the x-axis describes the time-to-discharge (days) and the y-axis 
describes the chance of patient response (%) to neutropenic fever for patients diagnosed 
with de-novo AML. The blue curve represents patients  with neutropenic fever and the 
green curve represents patients without neutropenic fever. It is important to note the 
differences between time-to-discharge (days) between the two curves shown in the graph. 
The blue curve (1) has a wider range and a higher mean time-to-discharge value compared 
to the green curve, indicating that patients in this group were discharged after a longer 
period of time. The last patient in each group was discharged at a different time, indicating 
that the presence and absence of neutropenic fever can affect the time-to-discharge (days). 
Whether the longer time-to-discharge (days) is due to poorer prognosis or treatment 
complications is unknown. 
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To determine whether these differences (shown above) in time-to-discharge (days) 
between patients with and without neutropenic fever were statistically significant and 
generalizable to the overall population, three comparison tests were conducted. The Log-
Rank Test, The Wilcoxon Test, and the Tarone-Ware Tests were performed to determine 
whether these differences were significant, and if so, where are they significant. The Log-
Rank test (table 3h) was performed to demonstrate whether these differences were 
significant later in time. The Wilcoxon test (table 3h) was performed to demonstrate 
whether these differences were significant earlier in time. The Tarone-Ware test (table 
3h) was performed to demonstrate whether these differences were significant in the time 
in between. The Null Hypotheses (H0) included the following: There were no differences 
in time-to-discharge (days) between the two groups compared in this analysis in the long-
term, short term, and in between. The Alternative Hypotheses (Ha) included the following: 
There were differences in the time-to-discharge (days) between the two groups compared 
in this analysis in the long term, short term, and in between.  
Table 3h. Comparison Tests for Kaplan-Meier Analysis #4  
Log-Rank Test: 
Since the value obtained (0.177) is greater than the alpha value of 0.05, it was determined 
that there was no statistical significant difference in time-to-discharge (days) between the 
two groups compared in the long term. Therefore we fail to reject the null hypothesis. There 
is no statistically significant difference in time-to-discharge (days) based on the presence 
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and absence of neutropenic fever in the group containing patients diagnosed with de-novo 
AML.  
Wilcoxon Test: 
Since the value obtained (0.293) is greater than the alpha value of 0.05, it is determined 
that there is no statistically significant difference in time-to-discharge (days) between the 
two groups compared in the short term. Therefore, it is appropriate to fail to reject the null 
hypothesis. There is no statistically significant difference in time-to-discharge (days) based 
on presence and absence of neutropenic fever obtained in the group containing patients 
diagnosed with de-novo AML.  
Tarone-Ware Test: 
Since the value obtained (0.244) is greater than the alpha value of 0.05, it is determined 
that there is no statistically significant difference in time-to-discharge (days) between the 
two groups compared in the time in between. Therefore, it is appropriate to fail to reject 
the null hypothesis. There is no statistically significant difference in time-to-discharge 
(days) based on the presence and absence of neutropenic fever in the group containing 
patients diagnosed with de-novo AML.  
The curves are not statistically significant based on their difference. Since there is no 
statistically significant difference, it cannot be concluded that the chances of effectiveness/ 
patient response to the intervention (%) examined are different from the overall population. 
Therefore, this means that the results obtained are reflective of differences in the overall 
population, and are therefore generalizable. The differences shown in the time-to-discharge 
(days) between two groups compared in this analysis was not statistically significant.   
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While there were no statistically significant differences found in time-to-discharge (days) 
within each disease group, it is important to note the mean-to-discharge (days) was higher 
in patients with de-novo AML in comparison to patients with AML with underlying MDS.  
 
Kaplan-Meier Analysis Results #5: 
Neutropenic Fever (AML with MDS)  
 
2f) The Kaplan-Meier Method was used to examine the effect of neutropenic fever on the 
time-to-discharge (days) in patients diagnosed with AML with underlying MDS. The two 
groups that were compared in this analysis included the following: Stratum 1 – Patients 
who had neutropenic fever; Stratum 2 – Patients who did not have neutropenic fever. The 
Status Variable was indicated as the following: 1 – Patients who were discharged; 0 – 
Patients who either withdrew from the study or died for unknown reasons. The time 
variable was indicated as the time-to-discharge (days) or the number of days the patient 
remained in the hospital. The Null Hypothesis (H0) was that there was no difference in 
time-to-discharge (days) between the two groups of patients diagnosed with AML with 
underlying MDS based on the presence or absence of neutropenic fever. The Alternative 
Hypothesis (Ha) was that there was a difference in time-to-discharge (days) between the 
two groups of patients diagnosed with AML with underlying MDS based on the presence 
or absence of neutropenic fever. The mean time-to-discharge (days) was calculated for each 
group and is illustrated in the table 3i below:  
Stratum # Mean Time-To-Discharge 
(days) 
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Stratum 1 –  Neutropenic Fever  23.867 
Stratum 2 –  No Neutropenic Fever 20.250 
Table 3i. Neutropenic Fever and Mean Time-To-Discharge (Days) – AML with MDS 
 
As shown in the table 3i above, the mean time-to-discharge (days) varied across the two 
groups observed in this analysis. Of the two groups, patients with neutropenic fever a 
higher mean time-to-discharge (23.867 days) than patients without neutropenic fever 
(20.250 days). The graphs to follow illustrate the effectiveness of neutropenic fever/ chance 
of patient response to neutropenic fever in relation to time-to-discharge (days) for patients 
diagnosed with AML with underlying MDS.  
Graph 5a. Survival Distribution Function: Patients with AML with underlying MDS – 
Neutropenic Fever  
     
On Graph 5a shown above, the x-axis describes the time-to-discharge (days) and the y-axis 
describes the chance of patient response (%) to neutropenic fever for patients diagnosed 
with AML with underlying MDS. At a time-to-discharge of 14 days, the chance of 
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effectiveness and patient response to neutropenic fever was approximately 100% in a 
patient diagnosed with AML with underlying MDS. At a time-to-discharge of 30 days, the 
patient response to neutropenic fever was 0.0% in a patient diagnosed with AML with 
underlying MDS. This graph illustrates that as the time-to-discharge (days) increases, the 
chance of patient response (%) to neutropenic fever decreases. The lower the patient 
response to neutropenic fever, the more time (days) that patients diagnosed with AML with 
underlying MDS are required to stay in the hospital.  
 
 
On Graph 5b shown above, the x-axis describes the time-to-discharge (days) and the y-axis 
describes the chance of patient response (%) to the absence of neutropenic fever for patients 
diagnosed with de-novo AML. At a time-to-discharge of 7 days, the chance of patient 
response to the absence of neutropenic fever was approximately 75% in a patient diagnosed 
with AML with underlying MDS. At a time-to-discharge of 28 days, the patient response 
to the absence of neutropenic fever was 0.05% in a patient diagnosed with AML with 
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underlying MDS. This graph illustrates that as the time-to-discharge (days) increases, the 
chance of patient response (%) to neutropenic fever decreases. The lower the patient 
response to neutropenic fever, the more time (days) that patients diagnosed with AML with 
underlying MDS are required to stay in the hospital. 
Graph 5c. Survival Distribution Function: Patients with AML with underlying MDS 
(Neutropenic Fever/No Neutropenic Fever)  
 
On Graph 5c shown above, the x-axis describes the time-to-discharge (days) and the y-axis 
describes the chance of patient response (%) to neutropenic fever for patients diagnosed 
with AML with underlying MDS. The blue curve represents patients with neutropenic fever 
and the green curve represents patients without neutropenic fever. It is important to note 
the differences between time-to-discharge (days) between the two curves shown in the 
graph. The blue curve (1) has a wider range and a higher mean time-to-discharge value 
compared to the green curve, indicating that patients in this group were discharged after a 
longer period of time. The last patient in each group was discharged at a different time, 
indicating that the presence and absence of neutropenic fever can affect the time-to-
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discharge (days). However, in this scenario, the difference between the two curves with 
respect to time-to-discharge (days) was very small. Whether this small difference is due to 
the nature of MDS or other treatment complications is unknown. 
To determine whether the small differences (shown above) in time-to-discharge (days) 
between patients with and without neutropenic fever were statistically significant and 
generalizable to the overall population, three comparison tests were conducted. The Log-
Rank Test, The Wilcoxon Test, and the Tarone-Ware Tests were performed to determine 
whether these differences were significant, and if so, where are they significant. The Log-
Rank test (table 5a) was performed to demonstrate whether these differences were 
significant later in time. The Wilcoxon test (table 5a) was performed to demonstrate 
whether these differences were significant earlier in time. The Tarone-Ware test (table 
5a) was performed to demonstrate whether these differences were significant in the time in 
between. The Null Hypotheses (H0) included the following: There were no differences in 
time-to-discharge (days) between the two groups compared in this analysis in the long-
term, short term, and in between. The Alternative Hypotheses (Ha) included the following: 
There were differences in the time-to-discharge (days) between the two groups compared 
in this analysis in the long term, short term, and in between.  
Table 3j. Comparison Tests for Kaplan-Meier Analysis #5  
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Log-Rank Test: 
Since the value obtained (0.598) is greater than the alpha value of 0.05, it was determined 
that there was no statistical significant difference in time-to-discharge (days) between the 
two groups compared in the long term. Therefore we fail to reject the null hypothesis. There 
is no statistically significant difference in time-to-discharge (days) based on the presence 
and absence of neutropenic fever in the group containing patients diagnosed with AML 
with underlying MDS.  
Wilcoxon Test: 
Since the value obtained (0.606) is greater than the alpha value of 0.05, it is determined 
that there is no statistically significant difference in time-to-discharge (days) between the 
two groups compared in the short term. Therefore, it is appropriate to fail to reject the null 
hypothesis. There is no statistically significant difference in time-to-discharge (days) based 
on presence and absence of neutropenic fever obtained in the group containing patients 
diagnosed with AML with underlying MDS.  
Tarone-Ware Test: 
Since the value obtained (0.619) is greater than the alpha value of 0.05, it is determined 
that there is no statistically significant difference in time-to-discharge (days) between the 
two groups compared in the in between period. Therefore, it is appropriate to fail to reject 
the null hypothesis. There is no statistically significant difference in time-to-discharge 
(days) based on the presence and absence of neutropenic fever in the group containing 
patients diagnosed with de-novo AML.  
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The curves are not statistically significant based on their difference. Since there is no 
statistically significant difference, it cannot be concluded that the chances of effectiveness/ 
patient response to the intervention (%) examined are different from the overall population. 
Therefore, this means that the results obtained are reflective of differences in the overall 
population, and are therefore generalizable. The differences shown in the time-to-discharge 
(days) between two groups compared in this analysis was not statistically significant.   
While there were no statistically significant differences found in time-to-discharge (days) 
within each disease group, it is important to note the mean-to-discharge (days) was higher 
in patients with de-novo AML in comparison to patients with AML with underlying MDS.  
 
 
 
DISCUSSION 
         
AML is a heterogeneous disease that is influenced by multiple factors. This clinical 
heterogeneity was illustrated through the use of the Chi-Square Test and Kaplan-Meier 
Analysis. As shown by Table 2a, a statistically significant difference was not found 
between the de-novo AML group and the AML with MDS group with respect to remission 
rate post-induction therapy in a community hospital setting. As shown by Table 2f, a 
statistically significant difference was not found between the de-novo AML group and 
AML with MDS group with respect to length of stay in a community hospital setting during 
induction therapy.   
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Each disease group was evaluated individually for variations in the following parameters: 
age at diagnosis, number of chromosomal abnormalities, blood transfusion requirements, 
and neutropenic fever as outlined in tables 2b, 2c, 2d, and 2e. A marginally significant 
difference was found in the de-novo AML group with respect to the association between 
age at diagnosis and remission status. This association indicates that younger patients 
diagnosed with de-novo AML could be more likely to benefit from therapy and achieve 
complete remission. However, a larger sample size will be required to establish this 
association and confirm this finding. A marginally significant difference was found in the 
AML with MDS group with respect to the number of chromosomal abnormalities. This 
indicates that perhaps patients diagnosed with AML with MDS who have one or more 
chromosomal abnormalities could benefit from therapy and achieve complete remission. 
However, a larger sample will be required to establish this association and confirm this 
finding. There was a trend towards better remission rates in patients ages 18-50 years of 
age compared to those greater than 50 years of age, which is similar to previously published 
data. Perhaps with a larger study population, a more significant p-value could have been 
obtained. However, in the AML with MDS group, there was a significant difference found 
with respect to the association between age at diagnosis and remission rate. (p value = 
0.017) This indicates that older patients are less likely to benefit from therapy and less 
likely to go into complete remission following induction therapy. Perhaps for this subset 
of patients, it would be beneficial to create less toxic therapeutic options to allow for 
optimal clinical response or consider supportive care only. Future studies with older patient 
populations should be considered to fully evaluate effective therapeutic options.  
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This study allowed for data collection and examination of clinical care in a community 
hospital setting. The impact of various predictors on clinical outcomes was able to 
examined through the use of an effective study design and robust statistical analysis. The 
information collected on length of stay would be helpful for establishing guidelines on 
insurance coverage in regards to disease status in a community hospital setting. While this 
important information was generated from this study, it is also important to consider some 
limitations of the study. The trends observed in remission rates and length of stay could 
have been generated and affected by the small sample size, lack of access to certain medical 
information due to the nature of a retrospective study, and rare nature of the disease of 
interest. It remains a question as to whether or not the results generated from this study are 
specific to this particular clinical environment or generalizable to the overall population. 
Perhaps with a larger sample size and increased access to medical records, a more 
significant difference and specific answers can be generated. It would also be helpful to 
consider other predictor variables that could have affected the results obtained from this 
study. Predictor variables such as hospital-acquired infections, other co-morbidities, 
previous treatments, duration of treatment, use of growth factors, age, and multiple 
treatment complications should be considered. In fact, invasion fungal infections remain 
one of the leading causes of morbidity, mortality, and economic burden for patients 
suffering with AML. A rise in the number of fungal infections has resulted in prolonged 
length of stay in hospitals and an increase in overall expenditures.23 While previous studies 
involving the use of growth factors have yielded mixed results, it would be beneficial to 
investigate the impact of growth factors on responses to chemotherapy and drug resistance 
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to current AML therapies in patients suffering with AML with underlying MDS.24 Perhaps 
investigating the number of fungal infections and use of growth factors in this patient 
population through a clinical trial, retrospective study, and prospective study would 
provide additional information regarding factors that affect remission status and length of 
stay. While this study only considered the prognosis of disease after induction therapy and 
patients ages 18 and older, perhaps it would also be useful to study the prognosis of only 
elderly patients over the full course of treatment. Older patients (ages 60 and older) tend to 
not tolerate the therapies as well due to other co-morbidities and poor tolerance to 
infections.25 Treating older patients suffering from de-novo AML and AML with MDS 
continues to be a clinical and therapeutic challenge. Future studies investigating factors 
that affect disease prognosis, treatment toxicity, resistance to therapy, and treatment-related 
infections in this patient population should be considered. These research endeavors will 
help improve the clinical care and allow for the a more thorough assessment of therapeutic 
strategies required for the AML and MDS patient population. 
 
CONCLUSION 
 
 AML continues to be a therapeutic and clinical challenge for researchers and clinicians 
alike. This study was able to consider both clinical and therapeutic predictors that affected 
remission status and length of stay within groups of individuals. While this study was able 
to pinpoint some differences between disease groups in regards to remission rates, the 
heterogeneous nature of the disease continues to make it difficult to develop specific 
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diagnostic tools and targeted therapies to specifically distinguish disease subtypes. The 
prognosis of individuals who are diagnosed with de-novo AML and AML with MDS can 
be affected by a variety of different factors such as chromosomal abnormalities, age, and 
infections. This information generated from this study can be used to design future studies 
to improve the quality of life, clinical outcomes, and costs associated with this disease. 
Efforts toward fighting off drug resistance should be also considered in the effort to 
improve clinical outcomes for affected individuals of all ages. The study will not only 
impact the focus of AML clinical care, but also provide insight into the clinical challenges 
faced by AML patients and clinicians in the community hospital setting.  
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Appendix 1: Medical Glossary26 
 
Hematopoiesis  -  the normal formation and development of blood cells in the bone 
marrow 
 
 
 
Myeloblasts – the earliest, recognizable precursor of leukocytes (white blood cells)  
 
 
 
Anemia – inadequate tissue oxygenation; usually caused by inadequate blood oxygen-
carrying capacity; may be caused by a decrease in erythrocyte production, an increase in 
erythrocyte destruction, or a loss of blood.  
 
 
 
 
Neutropenia – abnormal decrease in neutrophil (white blood cell count) associated with 
acute leukemia.  
 
 
 
 
Thrombocytopenia – a platelet count that is lower than reference interval (150,000 ul); 
may be a consequence of decreased production disorders such as acute leukemia 
 
 
 
 
 
Induction Therapy – initial treatment for cancer, especially as part of a combined 
modality therapy 
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